Why invest in coherus biosciences management? Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September. Coherus BioSciences Reports Corporate Highlights and Second Quarter 2019 Financial Results. At Coherus, we believe that biosimilars have the potential to help offset the increasing cost of healthcare.Why choose coherus? At Coherus, we put patients first. We are dedicated to improving the availability of high-value, high-quality therapeutics. Our pipeline spans multiple therapeutic areas including oncology, immunology, and ophthalmology. Our first product, UDENYCA ® (pegfilgrastim-cbqv), is an FDA-approved pegfilgrastim biosimilar.What is the co pay assistance program coherus? Coherus COMPLETE TM Co-Pay Assistance Program Coherus COMPLETE TM offers a Co-Pay Assistance Program that covers out-of-pocket expenses related to UDENYCA ® for commercially insured patients. Eligible patients qualify for $0 out-of-pocket costs for each UDENYCA ® dose.* $15,000 maximum
Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson. “Alan was truly a titan of the biotech industry, without peer in his discipline, and this is such tremendous loss on so many levels for so many people. His contributions and impact on the industry through its genesis and evolution are difficult to overstate.
Coherus BioSciences uses 1 email formats. The most common Coherus BioSciences email format is first_initial last (ex. [email protected] ) being used 100.0% of the time. Get Verified Emails for Coherus BioSciences Employees. Coherus BioSciences's Email Format.